Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.
Martin Kulldorff, PhD, is a respected biostatistician in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital + Harvard Medical School. He has long been working in infectious disease outbreaks, detection of new disease outbreaks, and developing novel epidemiological methods.
He has developed new sequential statistical methods for near real-time post-market drug and vaccine safety surveillance, where the purpose is to use weekly, monthly or other frequent data feeds to find potential safety problems as soon as possible.
As a biostatistician, Dr. Kulldorff also does collaborative and consulting work with epidemiologists and clinicians, using a wide variety of study designs and methods for many different types of diseases. Dr. Kulldorff received his bachelor’s degree in mathematical statistics from Umeå University in Sweden, and his doctorate in operations research from Cornell University.
[Bio courtesy of Harvard Medical School]
Related Coverage: Raj Bhopal Full Interview: COVID-19 Zugzwang | ContagionLive
